Moderna posted a revenue increase in the first quarter of 2026, fueled by stronger international sales of its COVID-19 vaccine. The company has been navigating a downturn in U.S. demand by leaning on overseas markets, a strategy that appears to be gaining traction.
International results helped compensate for falling U.S. vaccine sales, according to the company's earnings report. This marks a continued reversal from earlier struggles, as Moderna had previously faced a steep dropoff in revenue following the pandemic peak.
The earnings boost has propelled Moderna's stock price higher in 2026, extending a recovery that began late last year. Investors have responded positively to the company's ability to stabilize revenue amid a shifting vaccine landscape.
However, analysts caution that the rebound may be fragile. Dependence on international markets exposes Moderna to currency fluctuations, geopolitical risks, and varying vaccine adoption rates across countries. A resurgence of domestic competition or a new variant could also disrupt the current trajectory.
The company has not disclosed specific financial figures, but the earnings report underscores Moderna's ongoing pivot toward global markets as U.S. sales normalize. The results will likely factor into discussions about the firm's long-term strategy beyond COVID.